FDA/CDC

Hadlima approved as fourth adalimumab biosimilar in U.S.


 

The Food and Drug Administration has approved the Humira biosimilar Hadlima (adalimumab-bwwd), making it the fourth adalimumab biosimilar approved in the United States, the agency announced.

FDA icon Wikimedia Commons/FitzColinGerald/Creative Commons License

Hadlima is approved for seven of the reference product’s indications, which include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, and ulcerative colitis.

The product will launch in the United States on June 30, 2023. Other FDA-approved adalimumab biosimilars – Amjevita (adalimunab-atto), Cyltezo (adalimumab-adbm), Hyrimoz (adalimumab-adaz) – similarly will not reach the U.S. market until 2023.

Hadlima is developed by Samsung Bioepis and commercialized by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.

*This article was updated on July 24, 2019.

Recommended Reading

Infliximab biosimilar only moderately less expensive in Medicare Part D
MDedge Dermatology
Flu vaccination lags among patients with psoriasis
MDedge Dermatology
Glucocorticoids plus tofacitinib may boost herpes zoster risk
MDedge Dermatology
FDA approves adalimumab biosimilar Hyrimoz
MDedge Dermatology
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
MDedge Dermatology
Algorithm proposes approach for managing TNF inhibitor–induced psoriasis
MDedge Dermatology
Mediterranean diet cut Parkinson’s risk
MDedge Dermatology
TNF inhibitor prices rose despite increased drug class competition
MDedge Dermatology
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
MDedge Dermatology
FDA approves new etanercept biosimilar, Eticovo
MDedge Dermatology